BioStem Technologies, Inc.
BSEM
Rank in Stocks
#26305
BioStem Technologies, Inc. engages in the development, manufacturing, and... BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Share Price
$1.12
Last synced: 2026-11-09
Market Cap
$20.91M
Change (1 day)
-0.88%
Change (1 year)
-75.49%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade BioStem Technologies, Inc. (BSEM)
Category
Healthcare
Operating Margin for BioStem Technologies, Inc. (BSEM)
Operating Margin as of November 2026 TTM: 38.70%
According to BioStem Technologies, Inc.'s latest financial reports, its current operating margin (TTM) is 38.70%. At the end of 2025 the company had an operating margin of -1.45%.
Operating Margin history for BioStem Technologies, Inc. from 2010 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 38.70% | -2,768.97% |
| 2025 | -1.45% | -114.02% |
| 2024 | 10.34% | -122.18% |
| 2023 | -46.62% | -31.53% |
| 2022 | -68.09% | 84.08% |
| 2021 | -36.99% | -49.37% |
| 2020 | -73.06% | -66.46% |
| 2019 | -217.82% | -71.48% |
| 2018 | -763.62% | -48.06% |
| 2017 | -1,470.21% | 157.33% |
| 2016 | -571.33% | -63.34% |
| 2015 | -1,558.34% | 136.43% |
| 2014 | -659.11% | -55.17% |
| 2013 | -1,470.28% | 4,909.47% |
| 2012 | -29.35% | -24.08% |
| 2011 | -38.66% | 26.55% |
| 2010 | -30.55% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -99.00% |
US
|
|
| -149.01% | -103.85% |
US
|
|
| 25.57% | -99.34% |
AU
|
|
| 31.23% | -99.19% |
BE
|
|
| 29.35% | -99.24% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about BioStem Technologies, Inc.'s operating margin
What is BioStem Technologies, Inc.'s operating margin?
BioStem Technologies, Inc.'s operating margin is 38.70%, as of Nov 2026.
What was BioStem Technologies, Inc.'s operating margin in 2025?
In 2025, BioStem Technologies, Inc.'s operating margin was -1.45%, compared with 10.34% in 2024.
How has BioStem Technologies, Inc.'s operating margin changed since 2020?
From 2020 to 2025, BioStem Technologies, Inc.'s operating margin was highest in 2024 (10.34%) and lowest in 2020 (-73.06%).
How does BioStem Technologies, Inc.'s operating margin compare with similar companies?
BioStem Technologies, Inc.'s operating margin (38.70%) is higher than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.